MBRX News and Press, Moleculin Biotech Inc. From 04/11/22

/C O R R E C T I O N -- Moleculin Biotech, Inc./ PR Newswire In the news release, Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting, issued 08-Apr-2022 by Moleculin Biotech, Inc. over PR Newswire, we are advised b...

Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting PR Newswire Annamycin exhibited robust antitumor activity in experimental colorectal cancer liver and lung metastasis models Results support advancement of p...

Moleculin Biotech press release (NASDAQ:MBRX): FY GAAP EPS of -$0.59 beats by $0.12. Shares +3.33% PM. The company ended the year with $70.9M of cash. The company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase ...

Moleculin Reports Full Year Financial Results and Provides Programs Update PR Newswire – Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine – ...

Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest PR Newswire HOUSTON , March 23, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinic...

Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference Presentation with live webcast on Thursday, March 17th at 9:20 AM ET PR Newswire HOUSTON , March 11, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" o...

Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors - Biopharma executive and oncology physician-scientist with extensive experience in early and late clinical development with successful track record leading development of multiple oncology products fr...

Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development - Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine -...

Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference - Live video webcast presentation on Thursday, January 27th at 9:00 AM ET - PR Newswire HOUSTON , Jan. 20, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (...

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma - Review of preliminary interim data continues to demonstrate the absence of cardiotoxicity for Annamycin, repr...